- Home
- CBIO vs LEGT Comparison
CBIO vs LEGT Comparison
Compare CBIO & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CBIO | LEGT |
|---|---|---|
| Founded | 2003 | 2023 |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.4M | 282.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CBIO | LEGT |
|---|---|---|
| Price | $19.98 | $10.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 190.5K | 122.2K |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $355.04 | N/A |
| P/E Ratio | ★ N/A | $35.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $10.44 |
| 52 Week High | $18.50 | $11.50 |
Technical Indicators
Market Signals| Indicator | CBIO | LEGT |
|---|---|---|
| Relative Strength Index (RSI) | 82.43 | 52.75 |
| Support Level | $10.44 | $10.84 |
| Resistance Level | N/A | $11.10 |
| Average True Range (ATR) | 1.43 | 0.03 |
| MACD | 0.92 | -0.00 |
| Stochastic Oscillator | 95.41 | 23.44 |
Price Performance
Historical ComparisonAbout CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.